Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press100910.17650/1726-9776-2019-15-4-120-125REVIEWОБЗОРRenal cell carcinoma: what’s new in 2019Рак почки: что нового в 2019 годуhttps://orcid.org/0000-0002-3016-6357EvsyukovaО. I.ЕвсюковаО. И.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Ольга Игоревна Евсюкова, врач-онколог, аспирант отделения урологического

115478 Москва, Каширское шоссе, 24

dr.samuseva@gmail.comhttps://orcid.org/0000-0001-7748-9527MatveevV. В.МатвеевВ. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478

Всеволод Борисович Матвеев,  член-корреспондент РАН, профессор, заместитель директора по научной и инновационной работе, исполняющий обязанности заведующего отделением урологическим

115478 Москва, Каширское шоссе, 24

vsevolodmatveev@mail.ruN. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава России301220191541201251212201924122019https://oncourology.abvpress.ru/oncur/article/view/1009

This review of renal cell carcinoma describes new diagnostics and treatment standards, new guidelines from international professional organizations and key studies, published in 2019.

В настоящем обзоре, посвященном почечно-клеточному раку, описаны новые стандарты диагностики и лечения, новые рекомендации международных профессиональных организаций, а также ключевые исследования в области онкоурологии, представленные в 2019 г.

renal cell carcinomacytoreductive nephrectomymetastasectomytargeted therapyimmunotherapyпочечно-клеточный ракциторедуктивная нефрэктомияметастазэктомиятаргетная терапияиммунотерапияAxel E.M., Matveev V.В. Statistics of malignant tumors of urinary and male urogenital organs in Russia and the countries of the former USSR. Onkourologiya = Cancer Urology 2019;15(2):15‒24. (In Russ.). DOI: 10.17650/1726-9776-2019-15-2-15-24.Аксель Е.М., Матвеев В.Б. Статистика злокачественных новообразований мочевых и мужских половых органов в России и странах бывшего СССР. Онкоурология 2019;15(2):15‒24. DOI: 10.17650/1726-9776-2019-15-2-15-24.Ljungberg B., Albiges L., Bensalah K. et al. EAU Guidelines on Renal Cell Carcinoma. European Association of Urology 2019. р. 5.2.2.Campbell S.P., Baras A.S., Ball M.W. et al. Low levels of PSMA expression limit the utility of F-18-DCFPyL PET/CT for imaging urothelial carcinoma. Ann Nucl Med 2018;32:69–74. DOI: 10.1007/s12149-017-1216-x.Baccala A., Sercia L., Li J. et al. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007;70(2):385–90. DOI: 10.1016/j.urology.2007.03.025.Raveenthiran S., Esler R., Yaxley J., Kyle S. The use of 68Ga-PET/CT PSMA in the staging of primary and suspected recurrent renal cell carcinoma. Eur J Nucl Med Mol Imaging 2019;46(11):2280‒8. DOI: 10.1007/s00259-019-04432-2.Delahunt B., Dagher J., Egevad L. et al. Is the UICC/AJCC pT2 staging category for clear cell renal cell carcinoma meaningful? Am J Surg Pathol 2019;43(9):1249‒52. DOI: 10.1097/PAS.0000000000001308.Tan W.S., Berg S., Cole A. et al. Comparing long-term outcomes following radical and partial nephrectomy for cT1 renal cell carcinoma in young and healthy individuals. Eur Urol Suppl 2019;18(1):1423–4. DOI: 10.1016/s15699056(19)31027-9.Pecoraro A., Palumbo C., Knipper S. et al. Cryoablation predisposes to higher cancer specific mortality relative to partial nephrectomy in patients with nonmetastatic pt1b kidney сancer. J Urol 2019;202(6):1120‒6. DOI: 10.1097/JU.0000000000000460.Guo S., Yao K., He X. et al. Prognostic significance of laterality in renal cell carcinoma: A population-based study from the surveillance, epidemiology, and end results (SEER) database. Cancer Med 2019;8(12). DOI: 10.1002/cam4.2484.Kaag M.G., Toyen C., Russo P. et al. Radical nephrectomy with vena caval thrombectomy: a contemporary experience. BJU Int 2010;107(9): 1386–93. DOI: 10.1111/j.1464410x.2010.09661.x.Freifeld Y., Woldu S.L., Singla N. et al. Impact of hospital case volume on outcomes following radical nephrectomy and inferior vena cava thrombectomy. Eur Urol Oncol 2019;2(6):691‒8. DOI: 10.1016/j.euo.2018.10.005.Serena G., Gonzalez J., Gaynor J.J. et al. Pulmonary tumor embolization as early manifestation in patients with renal cell carcinoma and tumor thrombus: Perioperative management and outcomes J Card Surg 2019;34(10):1018–23. DOI: 10.1111/jocs.14182.Méjean A., Ravaud A., Thezenas S. et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. NEJM 2018;379(5):417–27. DOI: 10.1056/nejmoa1803675.Méjean A., Thezenas S., Chevreau C. et al. Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on CARMENA trial with focus on intermediate IMDC-risk population. J Clin Oncol 2019;37 Suppl. 15:4508. DOI: 10.1200/JCO.2019.37.15_suppl.4508Linehan W.M., Spellman P.T., Ricketts C.J. et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 2016;374(2):135–45. DOI: 0.1056/NEJMoa1505917.Graham J., Wells J.C., Donskov F. et al. Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: results from the International metastatic renal cell carcinoma database consortium. Eur Urol Oncol 2019;2(6):643‒8. DOI: 10.1016/j.euo.2019.03.007.Gao J., Karam J.A., Tannir N.M. et al. A pilot randomized study evaluating nivolumab (nivo) or nivo + bevacizumab (bev) or nivo + ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx). J Clin Oncol 2019;37 Suppl. 15:4501. DOI: 10.1200/JCO.2019.37.15_suppl.4501.Lyon T.D., Thompson R.H., Shah P.H. et al. Complete surgical metastasectomy of renal cell carcinoma in the postcytokine era. J Urol 2019. DOI: 10.1097/JU.0000000000000488.Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. NEJM 1–12 February 16, 2019. DOI: 10.1056/NEJMoa1816714.Rini B.I., Plimack E.R., Stus V. et al. Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study. J Clin Oncol 2019;37(15):4500. DOI: 10.1200/JCO.2019.37.15_suppl.4500.Motzer R.J., Tannir N.M., McDermott D.F. et al. Nivolumab plus Ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018;378:1277–90. DOI: 10.1016/j.eururo.2018.07.019.McDermott D.F., Choueiri T.K., Motzer J.R. et al. CheckMate 214 posthoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. J Clin Oncol 2019;37 Suppl. 15:4513. DOI: 10.1200/JCO.2019.37.15_suppl.4513.Tannir N.M., Arén F.O., Hammers H.J. et al. Thirty-month follow-up of the phase III CheckMate 214 trial of firstline nivolumab + ipilimumab (N + I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2019;37 Suppl. 7:547. DOI: 10.1200/JCO.2019.37.7_suppl.547.Rini B.I., Powles T., Atkins M.B. et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion 151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393(10189):2404‒15. DOI: 10.1016/s0140-6736(19)30723-8.Flaifel A., Xie W., Braun D.A. et al. PD-L1 expression and clinical outcomes to cabozantinib, everolimus and sunitinib in patients with metastatic renal cell carcinoma: analysis of the randomized clinical trials METEOR and CABOSUN. Clin Cancer Res 2019;25(20):1135. DOI: 10.1158/10780432.ccr-19-1135.Powles T., Larkin J.M.G., Patel P. et al. A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO). J Clin Oncol 2019;37 Suppl. 7:545. DOI: 10.1200/JCO.2019.37.7_suppl.545.Appleman L.J., Puligandla M., Pai S. et al. Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). J Clin Oncol 2019;37 Suppl. 15:4502. DOI: 10.1200/JCO.2019.37.15_suppl.4502.Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2019;380(12):1103‒15. DOI: 10.1056/NEJMoa1816047.Choueiri T.K., Albiges L., Haanen J.B.A.G. et al. Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol 2019; 37 Suppl. 15:101. DOI: 10.1200/ JCO.2019.37.15_suppl.101. DOI: 10.17650/1726‑9776‑2019‑15‑4-120-125Choueiri T.K., Albiges L., Haanen J.B.A.G. et al. Biomarker analyses from JAVELIN Renal 101: avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). J Clin Oncol 2019; 37 Suppl. 15:101. DOI: 10.1200/ JCO.2019.37.15_suppl.101. DOI: 10.17650/1726‑9776‑2019‑15‑4-120-125